A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: New molecular entities as object drugs

Clinical Pharmacokinetics

Volumn 49, Issue 11, 2010, Pages 703-727

  Venkatakrishnan, Karthik ^a   Pickard, Michael D ^a   Von Moltke, Lisa L ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Clinical trial design; Cytochrome P450; Dose prediction; Drug evaluation; Drug interactions; Metabolism; Pharmacokinetic modelling

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFINITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CYTOCHROME P450; DASATINIB; DISULFIRAM; DOCETAXEL; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; EVEROLIMUS; FLUVOXAMINE; IMATINIB; IRINOTECAN; ISONIAZID; IXABEPILONE; KETOCONAZOLE; LAPATINIB; LINEZOLID; NILOTINIB; OXCARBAZEPINE; PHENYTOIN; RIFAMPICIN; RITONAVIR; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VORINOSTAT;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; MAXIMUM TOLERATED DOSE; NOTE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 77957696701     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11536740-000000000-00000     Document Type: Note

References (89)

1. Huang SM, Lesko LJ. Drug-drug,drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 2004; 44 (6): 559-69
2. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31 (7): 815-32
3. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48 (6): 662-70
4. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81 (2): 298-304
5. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br J Clin Pharmacol 2001; 52 (1): 107-17
6. Zhang L, Reynolds KS, Zhao P, et al. Drug interactions evaluation: an in-tegrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 2010; 243 (2): 134-45
7. Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research, US FDA. Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling [draft]. Rockville (MD): FDA 2006 Sep [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Accessed 2010 Sep 1]
8. European Medicines Agency [EMA]. Guidelines on the investigation of drug interactions: draft [document reference CPMP/EWP/560/95/Rev. 1-Corr.*]. London: EMA, 2010 Apr 22 [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/05/ WC500090112.pdf [Accessed 2010 Sep 1]
9. Tykerb® (lapatinib) tablets: US prescribing information. Research Triangle Park(NC): GlaxoSmithKline, 2010 Apr [online]. Available from URL: http://us.gsk.com/products/assets/us-tykerb.pdf [Accessed 2010 Sep 1]
10. Torisel® (temsirolimus) injection: US prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals Inc., 2010 Jul [online]. Available from URL: http://www.pfizerpro.com/content/showlabeling.asp?id=490 [Accessed 2010 Sep 1]
11. Ixempra® (ixabepilone) injection: US prescribing information. Princeton (NJ): Bristol-Myers Squibb, 2010 May [online]. Available from URL: http://packageinserts.bms.com/pi/pi-ixempra.pdf [Accessed 2010 Sep 1]
12. Sutent® (sunitinib malate) capsules: US prescribing information. New York: Pfizer Labs, 2010 Jul [online]. Available from URL: http://www.pfizer.com/ files/products/uspi-sutent.pdf [Accessed 2010 Sep 1]
13. Tasigna® (nilotinib) capsules: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2010 Jun [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf [Accessed 2010 Sep 1]
14. Afinitor® (everolimus) tablets: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2010 Jun [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf [Accessed 2010 Sep 1]
15. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004; 54 (4): 290-4
16. Center for Drug Evaluation and Research, US FDA. Lapatinib (Tykerb®) new drug application number 22-059: clinical pharmacology and biopharmaceu-tics review. Rockville (MD): FDA 2007 Feb 26 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/022059s000-Clin PharmR.pdf [Accessed 2010 Sep 1]
17. Boni JP, Leister C, Burns J, et al. Differential effects of ketoconazole on ex-posure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008; 98 (11): 1797-802
18. Van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 in-hibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007; 13 (24): 7394-400
19. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89 (10): 1855-9
20. Venkatakrishnan K, Rader M, Ramanathan RK, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicen-ter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009; 31 (Pt 2): 2444-58
21. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75 (5): 448-54
22. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010; 116(6): 1582-91
23. Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 2008; 14 (9): 2701-9
24. Hisaka A, Kusama M, Ohno Y, et al. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet 2009; 48 (10): 653-66
25. Ito K, Hallifax D, Obach RS, et al. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005; 33 (6): 837-44
26. Lu C, Hatsis P, Berg C, et al. Prediction of pharmacokinetic drug-drug inter-actions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data: II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 2008; 36 (7): 1255-60
27. Lu C, Miwa GT, Prakash SR, et al. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotypic data. Drug Metab Dispos 2007; 35 (1): 79-85
28. Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cyto-chrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316 (1): 336-48
29. Obach RS, Walsky RL, Venkatakrishnan K, et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78 (6): 582-92
30. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative predic-tion of CYP3A4-mediated oral drug interactions based on the AUC increase bycoadministrationofstandarddrugs. Clin Pharmacokinet 2007;46(8): 681-96
31. OhnoY,Hisaka A, UenoM,et al. General framework for the predictionoforal drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47 (10): 669-80
32. Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictionsofcompounds asobjects of interaction. Br J Clin Pharmacol 2008; 65 (5): 680-92
33. Zhang H, Davis CD, Sinz MW, et al. Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 2007; 3 (5): 667-87
34. Miners JO, Mackenzie PI, Knights KM. The prediction of drug-glucuronida-tion parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 2010; 42 (1): 189-201
35. Kilford PJ, Stringer R, Sohal B, et al. Prediction of drug clearance by glucur-onidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 2009; 37 (1): 82-9
36. Balliet RM, Chen G, Gallagher CJ, et al. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69 (7): 2981-9
37. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65 (5): 576-82
38. Peterkin VC, Bauman JN, Goosen TC, et al. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 2007; 64 (4): 458-68
39. Kirby BJ, Unadkat JD. The impact of ignoring extraction ratio when pre-dicting drug-drug interactions, fraction metabolized and intestinal first-pass contribution. Drug Metab Dispos. Epub 2010 Aug 19
40. Galetin A, Gertz M, Houston JB. Potential role of intestinal first-pass meta-bolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 2008; 4 (7): 909-22
41. Galetin A, Hinton LK, Burt H, et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007; 8 (7): 685-93
42. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32 (2): 259-66
43. Tang H, Mayersohn M. A global examination of allometric scaling for pre-dicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006; 95 (8): 1783-99
44. Abe K, Bridges AS, Brouwer KL. Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 2009; 37 (3): 447-52
45. Ghibellini G, Vasist LS, Leslie EM, et al. In vitro-in vivo correlation of hepa-tobiliary drug clearance in humans. Clin Pharmacol Ther 2007; 81 (3): 406-13
46. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human popu-lations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24 (1): 53-75
47. Jamei M, Marciniak S, Feng K, et al. The Simcyp® population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5 (2): 211-23
48. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Simcyp) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008; 64 (1): 31-41
49. Rostami-Hodjegan A, Tucker G. 'In silico' simulations to assess the 'in vivo' consequences of'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technologies 2004; 1 (4): 441-8
50. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6 (2): 140-8
51. Roffey SJ, Obach RS, Gedge JI, et al. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007; 39 (1): 17-43
52. Benet LZ. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol 2010; 106 (3): 162-7
53. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9 (3): 215-36
54. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: trans-port/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22 (1): 11-23
55. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 2009; 6 (6): 1631-43
56. HiranoM, MaedaK, Shitara Y, etal. Contribution ofOATP2(OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311 (1): 139-46
57. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723
58. Yamada A, Maeda K, Kamiyama E, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 2007; 35 (12): 2166-76
59. Yamashiro W, Maeda K, Hirouchi M, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34 (7): 1247-54
60. Poirier A, Cascais AC, Funk C, et al. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 2009; 36 (6): 585-611
61. Poirier A, Funk C, Scherrmann JM, et al. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 2009; 6 (6): 1716-33
62. Watanabe T, Kusuhara H, Maeda K, et al. Physiologically based pharm-acokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328 (2): 652-62
63. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interin-dividual variability in response to drugs. J Clin Pharmacol 2007; 47 (5): 566-78
64. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007; 37 (10-11): 1196-224
65. Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299 (3): 849-57
66. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. Epub 2010 Apr 6
67. Yang J, Jamei M, Yeo KR, et al. Prediction of intestinal first-pass drug meta-bolism. Curr Drug Metab 2007; 8 (7): 676-84
68. Almond LM, Yang J, Jamei M, etal. Towards aquantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 2009; 10 (4): 420-32
69. Chu V, Einolf HJ, Evers R, et al. In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America Perspective. Drug Metab Dispos 2009; 37 (7): 1339-54
70. Mahr G, Sorgel F, Granneman GR, et al. Effects of temafloxacin and cipro-floxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet 1992; 22 Suppl. 1: 90-7
71. Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly in-creases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004; 76 (6): 598-606
72. Turpeinen M, TolonenA, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77 (6): 553-9
73. Preskorn SH. Clinically relevant pharmacology of selective serotonin reup-take inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
74. Fetell MR, Grossman SA, Fisher JD,et al. Preirradiation paclitaxel in glioblas-toma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J Clin Oncol 1997; 15 (9): 3121-8
75. Gilbert MR, Supko JG, Batchelor T, etal. Phase Iclinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003; 9 (8): 2940-9
76. Prados MD, Yung WK, Wen PY, et al. Phase-1 trial of gefitinib and temo-zolomide in patients with malignant glioma: a North American Brain Tumor Consortium study. Cancer Chemother Pharmacol 2008; 61 (6): 1059-67
77. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006; 12 (3 Pt 1): 860-8
78. Relling MV, Hoffman JM. Should pharmacogenomic studies be required for new drug approval? Clin Pharmacol Ther 2007; 81 (3): 425-8
79. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83 (1): 160-6
80. Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007; 82 (4): 410-26
81. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50 (4): 769-71
82. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81 (2): 228-34
83. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its pos-sible consequences. Pharmacogenomics 2004; 5 (3): 243-72
84. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in res-ponse to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84 (3): 417-23
85. Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007; 321 (2): 553-63
86. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34 (8): 1317-27
87. Dennison JB, Mohutsky MA, Barbuch RJ, et al. Apparent high CYP3A5 ex-pression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 2008; 327 (1): 248-57
88. Williams JA, Johnson K, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmaco-kinetics. J Clin Pharmacol 2006; 46 (3): 258-64
89. Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobio-tica 2004; 34 (2): 151-78